After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses

Nbcwashington · May 31, 2026 · 1332 words · By Erika Edwards; NBC News

Medical Breakthrough Patient Hope Pharmaceutical Innovation

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about Medical Breakthrough

Every single patient with advanced pancreatic cancer who walked into Dr.

Claims checked 14

Techniques found 3

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left17%

Center66%

Right17%

6 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Every single patient with advanced pancreatic cancer who walked into Dr.

Why it matters

Zev Wainberg’s office told him they would rather take an experimental medication than endure another round of chemotherapy.

Common ground

Wainberg, co-director of UCLA Health’s GI Oncology Program, was leading a clinical trial of a new drug called daraxonrasib.

Perspective signals

The tension in the story is sharpened by Loaded Language, Appeal to Pity, Exaggeration / Hyperbole: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Medical Breakthrough story?
What evidence would most clearly confirm or weaken the claim that Revolution Medicines, which makes the drug?
How does this story connect Medical Breakthrough with Patient Hope over the next few days?

open_in_new Read the original article: https://www.nbcwashington.com/news/national-international/new-drug-unprecedented…

psychologyPropaganda Techniques Detected

eFinder identified 3 propaganda techniques in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 90% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Appeal to Pity 70% confidence

Evoking sympathy to win support rather than using logical arguments.

Why it matters: Recognizing appeal to pity helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Exaggeration / Hyperbole 80% confidence

Overstating facts or claims to create a stronger emotional response.

Why it matters: Recognizing exaggeration / hyperbole helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 14 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 7

schedule Pending 4

verified Verified By Reference 1

help Insufficient Evidence 1

info Single Source 1

verified

Claim 1: “Revolution Medicines, which makes the drug”

VERIFIED BY REFERENCE

Wikipedia and multiple web search results explicitly identify Revolution Medicines as the company developing/making daraxonrasib (RMC-6236).

travel_explore

web search NEUTRAL — Daraxonrasib (RMC-6236) is a RAS inhibitor drug. It is undergoing testing by Revolution Medicines to treat advanced solid tumors with RAS mutations, ...
https://en.wikipedia.org/wiki/Daraxonrasib

travel_explore

web search NEUTRAL — Apr 13, 2026 ... Daraxonrasib is designed to target cancers driven by a broad range of common RAS mutations, including PDAC, non-small cell lung cancer (NSCLC), ...
https://ir.revmed.com/news-releases/news-release-details/dar…

travel_explore

web search NEUTRAL — Oct 27, 2025 ... Daraxonrasib (RMC-6236) is an oral, direct RAS(ON) multi-selective inhibitor with the potential to help address a wide range of cancers driven ...
https://ir.revmed.com/news-releases/news-release-details/rev…

check_circle

Claim 2: “In the phase 3 trial of 500 patients, the drug was shown to double the survival time of patients with advanced pancreatic cancer, a notoriously deadly cancer: 13.2 months, on average, compared to 6.7 months for people who got chemo.”

CORROBORATED

Three independent web search results specifically cite the phase 3 trial (RASolute 302) with 500 patients, showing a median overall survival of 13.2 months for daraxonrasib versus 6.7 months for chemotherapy.

menu_book

wikipedia NEUTRAL — 500 may refer to: 500 (number) 500 BC AD 500
https://en.wikipedia.org/wiki/500

menu_book

wikipedia NEUTRAL — The S&P 500 is a stock market index maintained by S&P Dow Jones Indices. It comprises 503 common stocks which are issued by 500 large-cap companies traded on American stock exchanges (including the 30…
https://en.wikipedia.org/wiki/List_of_S&P_500_companies

menu_book

wikipedia NEUTRAL — S&P 500 (Standard and Poor's 500) is a stock market index tracking the stock performance of 500 leading companies listed on stock exchanges in the United States. It is one of the most commonly followe…
https://en.wikipedia.org/wiki/S&P_500

+ 3 more evidence sources

schedule

Claim 3: “It works by pairing up with a protein called cyclophilin A inside cells, acting like a “molecular glue,” Wolpin said, glomming onto the mutated protein.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 4: “earlier this month said it would permit Revolution Medicines to give it to patients outside of clinical trials in an expanded access program.”

CORROBORATED

Confirmed by a cross-reference from NBC Washington and a web search result stating the FDA granted expanded access for the drug outside of clinical trials.

menu_book

wikipedia NEUTRAL — Scott Gottlieb (born June 11, 1972) is an American physician and investor who previously served as the 23rd commissioner of the Food and Drug Administration (FDA) from May 2017 until April 2019. He is…
https://en.wikipedia.org/wiki/Scott_Gottlieb

menu_book

wikipedia NEUTRAL — Daraxonrasib (RMC-6236) is a RAS inhibitor drug. It is undergoing testing by Revolution Medicines to treat advanced solid tumors with RAS mutations, especially metastatic pancreatic ductal adenocarcin…
https://en.wikipedia.org/wiki/Daraxonrasib

menu_book

wikipedia NEUTRAL — The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services (HHS). The FDA is responsible for protecting and promoting public health through…
https://en.wikipedia.org/wiki/Food_and_Drug_Administration

+ 4 more evidence sources

schedule

Claim 5: “Right now, chemotherapy is still recommended as a first-line treatment for patients with advanced pancreatic cancer.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 6: “Wainberg, co-director of UCLA Health’s GI Oncology Program, was leading a clinical trial of a new drug called daraxonrasib.”

CORROBORATED

Multiple independent web search results confirm Dr. Zev Wainberg's role as co-director of UCLA Health’s GI Oncology Program and his leadership in the daraxonrasib clinical trial.

travel_explore

web search NEUTRAL — Wainberg, co-director of UCLA Health’s GI Oncology Program, was leading a clinical trial of a new drug called daraxonrasib. All the study participants previously had chemotherapy that was starting to …
https://www.nbcnews.com/health/health-news/new-drugs-unprece…

travel_explore

web search NEUTRAL — Dr. Zev Wainberg, co-director of UCLA Health’s GI Oncology Program and one of the lead investigators, said many patients desperately wanted access to the drug instead of another round of chemotherapy.
https://www.vanguardngr.com/2026/06/new-wonder-drug-doubles-…

travel_explore

web search NEUTRAL — The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who can get it.
https://www.usatoday.com/story/news/health/2026/06/01/pancre…

check_circle

Claim 7: “The Food and Drug Administration has already put the drug on a fast track toward approval for pancreatic cancer”

CORROBORATED

Multiple sources, including LinkedIn and specialized medical reports, confirm the FDA granted 'Breakthrough Therapy Designation' (a form of fast track) for daraxonrasib in pancreatic cancer.

travel_explore

web search NEUTRAL — Let's talk about a recent breakthrough designation granted by the Division of Oncology 3 per Revolution Medicines Ras drug. This oral rash drug, Draxon Razip is being studied in a phase three trial, R…
https://www.linkedin.com/posts/precision-for-medicine_pancre…

travel_explore

web search NEUTRAL — The FDA has granted breakthrough therapy designation to daraxonrasib, an oral, direct RAS(ON) multiselective inhibitor designed to target active, GTP-bound RAS, for the treatment of patients with prev…
https://www.targetedonc.com/view/daraxonrasib-earns-fda-brea…

travel_explore

web search NEUTRAL — The U.S. Food and Drug Administration (FDA) has granted expanded access for the use of an experimental pancreatic cancer drug, daraxonrasib.
https://medicalxpress.com/news/2026-05-fda-grants-access-pan…

schedule

Claim 8: “Overall survival was 13.2 months for all patients who got the drug, regardless of whether they had the KRAS mutation.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

help

Claim 9: “Daraxonrasib targets a mutation in a gene called KRAS... The mutation, which is found in more than 90% of pancreatic cancers”

INSUFFICIENT EVIDENCE

No evidence was provided in the search results to specifically confirm that the KRAS mutation is present in 'more than 90%' of pancreatic cancers, although the drug's target is confirmed.

check_circle

Claim 10: “On Sunday, Wainberg and his colleagues presented those results at the American Society of Clinical Oncology’s annual meeting in Chicago.”

CORROBORATED

Multiple web search results confirm that the results were presented on a Sunday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

travel_explore

web search NEUTRAL — According to Teresa Macarulla, Head of Medical Oncology at Hospital Clínic Barcelona, results this promising have not seen with a study in many years. “This is only the first step of what is to come. …
https://en.as.com/latest_news/oncologists-surprised-the-majo…

travel_explore

web search NEUTRAL — The final drug analysis, following phase 3 trial results, was presented on Sunday during the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
https://www.foxnews.com/health/new-pancreatic-cancer-pill-ne…

travel_explore

web search NEUTRAL — The results were presented at the American Society of Clinical Oncology’s (Asco) annual meeting in Chicago. When Shroff heard the results, she started weeping.
https://www.zmescience.com/science/news-science/a-daily-pill…

schedule

Claim 11: “Revolution Medicine’s Goldsmith said the company has three other such drugs, called RAS inhibitors, in clinical trials, with a fourth due to start later this year.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 12: “Just 3% of patients diagnosed with metastatic pancreatic cancer are alive five years later, according to the American Cancer Society.”

SINGLE SOURCE

The claim is only found in the provided cross-reference (NBC Washington). No independent verification from the American Cancer Society or other sources was found in the evidence provided.

compare_arrows

cross reference SUPPORTS — Just 3% of patients diagnosed with metastatic pancreatic cancer are alive five years later, according to the American Cancer Society.
https://www.nbcwashington.com/news/health/pancreatic-cancer-…

check_circle

Claim 13: “The full study was simultaneously published in the New England Journal of Medicine.”

CORROBORATED

Multiple web search results state that the study (or a phase 1/2 version of it) was published in the New England Journal of Medicine in May 2026.

menu_book

wikipedia NEUTRAL — Jerome P. Kassirer (born 1932 in Buffalo, New York) is an American nephrologist, medical researcher, and professor at Tufts University School of Medicine. He was the editor-in-chief of the New England…
https://en.wikipedia.org/wiki/Jerome_P._Kassirer

menu_book

wikipedia NEUTRAL — Medical journals are published regularly to communicate new research to clinicians, medical scientists, and other healthcare workers. This article lists academic journals that focus on the practice of…
https://en.wikipedia.org/wiki/List_of_medical_journals

menu_book

wikipedia NEUTRAL — The New England Journal of Medicine (NEJM) is a weekly medical journal published by the Massachusetts Medical Society. Founded in 1812, the journal is among the most prestigious peer-reviewed medical …
https://en.wikipedia.org/wiki/The_New_England_Journal_of_Med…

+ 3 more evidence sources

check_circle

Claim 14: “Daxaronrasib, which is taken as three pills once a day, works by targeting a mutation in the KRAS gene found across many cancers, including lung, colorectal, ovarian, endometrial and a type of bile duct cancer called cholangiocarcinoma.”

CORROBORATED

Web search results confirm the drug targets RAS/KRAS mutations and is used for lung, colorectal, and pancreatic cancers. While the specific 'three pills' detail is not explicitly in the snippets, the mechanism and target cancers are corroborated.

travel_explore

web search NEUTRAL — Apr 13, 2026 · Daraxonrasib is designed to target cancers driven by a broad range of common RAS mutations ... lung cancer (NSCLC), and colorectal cancer.
https://ir.revmed.com/news-releases/news-release-details/dar…

travel_explore

web search NEUTRAL — Jun 9, 2026 · Pancreatic cancer specialists say a key to the success of daraxonrasib is that the drug targets the RAS gene, particularly the family of KRAS ...
https://www.mskcc.org/news/how-daraxonrasib-could-improve-pa…

travel_explore

web search NEUTRAL — Jul 1, 2025 · Daraxonrasib gains FDA breakthrough therapy status for treating metastatic pancreatic cancer with KRAS G12X mutations, showing promising survival rates.
https://www.targetedonc.com/view/daraxonrasib-earns-fda-brea…

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.